North America’s medical devices industry saw a rise of 25.00% in cross border deal activity during March 2021, when compared with the last 12-month average, led by Organon &’s $240m acquisition of Alydia Health , according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 20 medical devices industry cross border deals worth $919.51m were announced for the region in March 2021, against the 12-month average of 16 deals.
Of all the deal types, venture financing saw most activity in March 2021 with ten transactions, representing a 50% share for the region.
In second place was M&A with eight deals, followed by private equity deals with two transactions, respectively capturing a 40% and 10% share of the overall cross border deal activity for the month.
In terms of value of cross border deals, M&A was the leading category in North America’s medical devices industry with $488m, while venture financing and private equity deals totalled $310.51m and $121m, respectively.
North America medical devices industry cross border deals in March 2021: Top deals
The top five medical devices cross border deals accounted for 63.4% of the overall value during March 2021.
The combined value of the top five medical devices cross border deals stood at $583m, against the overall value of $919.51m recorded for the month.
The top five medical devices industry cross border deals of March 2021 tracked by GlobalData were:
1) Organon &’s $240m acquisition of Alydia Health
2) The $110m acquisition deal with 7D Surgical by SeaSpine
4) The $81m private equity deal with Rapid Micro Biosystems by Adage Capital Management , Ally Bridge Group , Asahi Kasei Medical , Bain Capital Life Sciences , BlackRock , CaaS Capital Management , D1 Capital Partners , Endeavour Vision , Longitude Capital Management Co, Quaker Partners Management, Sunley House Capital Management , T Rowe Price Associates and Xeraya Capital Sdn